Norman T R, Burrows G D
Department of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
J Neural Transm Suppl. 1989;28:53-63.
Monoamine oxidase inhibitors are effective in the treatment of panic attacks. Phenelzine has been used most often with good effect and is regarded by some as the treatment of first choice for panic disorders. Nevertheless the potential dangers of the use of non-specific MAOIs are well recognised and there is a need for safer drugs. The efficacy of specific MAO inhibitors such as moclobemide (MAO-A) and deprenyl (MAO-B) are yet to be investigated. The activity of the enzyme MAO in blood platelet (MAO-B) has been extensively studied. A review of early findings of elevated MAO activity suggests a number of reasons why the data should be interpreted with caution. Recent studies do not support the earlier findings and suggest no difference in platelet MAO activity between patients and controls. Similarly studies of the endogenous MAO inhibitor, tribulin, suggest that the output in panic disorder patients is similar to that of controls. Studies of the effectiveness of specific MAOIs in panic attacks are warranted as are further studies of the biochemical aetiology.
单胺氧化酶抑制剂对惊恐发作的治疗有效。苯乙肼使用最为频繁,效果良好,一些人将其视为惊恐障碍的首选治疗药物。然而,使用非特异性单胺氧化酶抑制剂的潜在风险已得到充分认识,因此需要更安全的药物。特异性单胺氧化酶抑制剂如吗氯贝胺(单胺氧化酶-A)和司来吉兰(单胺氧化酶-B)的疗效尚待研究。血小板中的单胺氧化酶(单胺氧化酶-B)活性已得到广泛研究。对单胺氧化酶活性升高的早期研究结果进行综述后发现,有诸多理由需谨慎解读这些数据。近期研究并不支持早期研究结果,表明患者与对照组的血小板单胺氧化酶活性并无差异。同样,对内源性单胺氧化酶抑制剂刺蒺藜素的研究表明,惊恐障碍患者的排出量与对照组相似。有必要开展特异性单胺氧化酶抑制剂对惊恐发作疗效的研究,同时也需要进一步研究生化病因。